Connect with us
  • tg

Stock Markets

Revance Therapeutics stock price target cut on first quarter performance

letizo News

Published

on

On Friday, Piper Sandler adjusted its outlook on Revance Therapeutics (NASDAQ:), reducing the stock price target to $11 from the previous $20, while maintaining an Overweight rating on the stock. The adjustment comes after Revance reported first-quarter financial results, revealing an adjusted net loss per share of $0.43 and revenue of $51.9 million.

These figures stood in contrast to the Street’s expectations, which anticipated a slightly higher loss per share of $0.46 and revenue of $56.4 million.

Despite the lowered stock price target, the firm’s analysts believe Revance is on track to meet its 2024 net sales goal of at least $280 million, a figure that is slightly below the consensus estimate of approximately $292 million. The company’s management has indicated that more than half of these sales are projected to come from its RHA product line, according to commentary from Revance.

Revance’s Daxxify, a product used in facial aesthetics, is showing promising performance with sales annualizing to nearly $90 million after five full quarters in the market. Moreover, the RHA franchise is annualizing at about $120 million in sales, approximately three years after its launch.

The first quarter is typically the slowest in the facial aesthetics industry, yet these figures suggest potential for the company to reach its stated top-line goals for the year.

The firm’s analysis suggests that Revance Therapeutics has a “fighting chance” of achieving its 2024 revenue targets. The analysts forecast that the company could reach a break-even point sometime in 2025. The revised price target of $11, down from $20, reflects more conservative estimates for Daxxify and RHA sales beyond the year 2024.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.

InvestingPro Insights

Piper Sandler’s recent price target adjustment for Revance Therapeutics (NASDAQ:RVNC) to $11 coincides with some critical financial metrics and market performance data. According to InvestingPro Data, Revance’s market capitalization stands at $447.08 million, with a significant revenue growth of 76.55% in the last twelve months as of Q4 2023. This growth is notable, especially considering the company’s revenue of $234.04 million in the same period.

Despite this revenue upswing, Revance’s profitability challenges are evident. The company’s P/E ratio is negative, at -1.85, and it has not been profitable over the last twelve months. This aligns with the InvestingPro Tip that analysts do not anticipate the company will be profitable this year. Moreover, the stock price has experienced a considerable decline over the last year, with a 1 Year Price Total Return of -88.15%.

Still, there is a silver lining. Revance’s liquid assets exceed its short-term obligations, suggesting a degree of financial stability. Moreover, the company has seen a significant return over the last week, with a 1 Week Price Total Return of 8.61%. This could indicate investor optimism in the short term, potentially reflecting confidence in the company’s strategic direction or product offerings.

For those interested in a deeper analysis, InvestingPro offers additional insights on Revance Therapeutics. There are more InvestingPro Tips available, which could further guide investment decisions. To explore these tips and gain more detailed financial insights, consider using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Stock Markets

S&P 500 rebounds as dip buyers pile into batter tech stocks; Fed meeting eyed

letizo News

Published

on

Continue Reading

Stock Markets

China’s DeepSeek prompts global sell-off in AI-linked stocks

letizo News

Published

on

Continue Reading

Stock Markets

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Five9, Inc. Investors to Secure Counsel Before Important February 3 Deadline in Securities Class Action – FIVN

letizo News

Published

on

New York, New York–(Newsfile Corp. – January 26, 2025) – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities, including call options, of Five9, Inc. (NASDAQ: NASDAQ:) between June 4, 2024 and August 8, 2024, both dates inclusive (the “Class Period”), of the important February 3, 2025 lead plaintiff deadline.

SO WHAT: If you purchased Five9 securities or call options during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Five9 class action, go to https://rosenlegal.com/submit-form/?case_id=32046 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 3, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action (WA:) Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Five9’s net new business was not “strong irrespective of the macro” and was, in fact, hampered by macroeconomic issues such as constrained and scrutinized customer budgets; (2) Five9 was in the midst of a challenging bookings quarter due, in part, to sales execution and efficiency issues, and Five9 was not “seeing very strong bookings momentum”; and (3) defendants did not have “enough information in terms of [their] existing customers that are going live” such that the statements that Five9 would see a positive inflection in its dollar-based retention rate lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Five9 class action, go to https://rosenlegal.com/submit-form/?case_id=32046 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook (NASDAQ:): https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/238378

Continue Reading

Trending

©2021-2024 Letizo All Rights Reserved